| INTRODUC TI ON
Haemophilia B is an X-linked hereditary bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). Treatment consists of prophylactic or on-demand replacement therapy with recombinant or plasma-derived FIX concentrates. However, replacement therapy with factor concentrates is costly. In the United Kingdom, 60 million international units of FIX concentrates are administered annually in 663 haemophilia B patients. 1 This will most probably increase further in the near future, due to the ageing haemophilia patient population and necessity of orthopaedic surgery for joint replacement.
In the perioperative setting, patients are generally treated with FIX concentrates for 7-10 consecutive days postoperatively.
Efficacious perioperative treatment is of importance to prevent underdosing with a risk of bleeding and overdosing with a possible risk of thrombosis and waste of expensive concentrates. However, treatment is complex due to a large interpatient variability, which is not taken into account in National guidelines. Recently, we identified both underdosing and overdosing in perioperative haemophilia A patients and the need for optimization of treatment strategies. 2 Collected data were subsequently used to construct a population pharmacokinetic (PK) model, currently being validated in a randomized controlled trial. 3 Few studies have reported on safety and efficacy of perioperative management in haemophilia B. 4, 5 Therefore, studies in these patients are vital to optimize treatment.
To evaluate current perioperative management in severe and moderate-severe haemophilia B patients and to identify predictive factors of low and high FIX levels, we conducted an international multicentre retrospective observational study to collect FIX levels after FIX concentrate administration during and after minor and major surgery as well as clinical outcome measures (FIX consumption and bleeding/thrombotic complications).
| ME THODS

| Patients
In this international multicentre retrospective observational cohort study, patients were included with severe and moderate haemophilia 
| Methods
The following information was extracted from the medical notes: pa- Also the influence of a clinically relevant bleeding complication was evaluated. In calculations of total perioperative FIX consumption, only FIX concentrate administered during the hospitalization period and during first surgical procedure in each individual patient was included.
| Statistical analysis
The nonparametric Mann-Whitney U test was used for comparison of 
| RE SULTS
A total of 118 severe and moderate haemophilia B patients who underwent a total of 255 surgical procedures were included. Of these, 85 (72%) were severe haemophilia B patients, of which 36 were on prophylactic treatment. Patient characteristics are shown in Table 2 P < .001). In accordance with guidelines, FIX consumption was highest on day 1 in both adults and children. Strikingly, FIX consumption did not decrease as prescribed during hospitalization from day 2 until day 7 (P for trend = .92; Figure 1 ). Patients with a minor surgical procedure were admitted for a median of 3 days (IQR 25% and 75% range: 1-5 days) and with a major surgical procedure for a median of 8 days (IQR 3-13 days).
| Perioperative complications
In only 3 (1.2%) surgical procedures, clinically relevant bleeding complications were observed. Two of these 3 patients underwent total knee replacements followed by haemarthrosis requiring a second intervention. One of these 3 patients received a red blood cell TA 
| Observed FIX levels and comparison to target ranges
No differences were observed between observed FIX levels between treatment centres and between countries. Daily monitoring of FIX levels revealed that most perioperative FIX levels were outside specified target ranges (Figure 2 ] 6 days after surgery.
F I G U R E 1
Perioperative FIX consumption on consecutive days. Overview of FIX consumption on consecutive postoperative days postoperatively. The amount of FIX administered factor concentrates was higher on day 1 in comparison with following days. P for trend analysis using one-way ANOVA showed no differences between amounts of FIX concentrates administered postoperatively F I G U R E 2 Achieved trough and steady-state FIX levels in the perioperative period. Achieved trough and steady-state FIX levels are shown for both patients treated by bolus infusion replacement therapy (blue) and by continuous infusion (red). Bolus infusion therapy was predictive of lower levels in the first 24 h after surgery in comparison with replacement therapy by continuous infusion. Frequency of lower and higher FIX levels than target range with median difference in IU mL −1 and corresponding 25-75% interquartile range (IQR) during the perioperative period is shown corresponding to specified target ranges (green) as defined by National and/or hospital guidelines
| Predictors of lower and higher FIX levels than target range
When analysing the complete perioperative period in the total study population, both treatments by bolus infusion and minor surgical procedures were predictive of lower FIX levels than required by guidelines (respectively, OR = 5.4 95% CI 3.5-8.3, OR = 2.0 95% CI 1.2-3.2).
During the first 24 hours after surgery, only bolus infusion was predictive of lower FIX levels in comparison with continuous infusion (OR = 6.1 95% CI 2.8-13.4; Table 3 ). Occurrence of a clinically relevant bleeding complication and treatment with continuous infusion were associated with excessively high FIX levels (≥0.20 IU mL −1 above target). No differences were observed between achieved FIX levels between treatment centres or between countries and/or between product type (plasma derived versus recombinant) (data not shown).
| D ISCUSS I ON AND CON CLUS I ON
This is the largest cohort of perioperative haemophilia B patients described to date with a total of 255 surgical procedures in 118 patients. This study demonstrates the challenges of perioperative FIX concentrate dosing as most perioperative FIX levels were outside the predefined target ranges recommended by National and/or hospital guidelines. Importantly, 60% of trough and steady-state FIX levels were below the target level in the first 24 hours after surgery, while 59% of FIX levels were above target more than 6 days after surgery. Despite the lower FIX levels, clinically relevant bleeding complications were uncommon (3/255, 1.2%).
The lower FIX levels observed immediately after surgery in our study are most likely due to increased clearance of FIX concentrate during and directly after surgery 4 as well as in- 
| Study strengths and limitations
The large number of patients, 118 patients, and variety of surgical of current guidelines with regard to target ranges as well as towards implementation of alternative dosing strategies based on more specific criteria than body weight and crude estimations of clearance, as the high proportion of FIX levels within 24 hours after surgery was not associated with a bleeding risk.
| Perioperative bleeding
Overall in our study population, perioperative bleeding in haemophilia B in both countries was rare (1.2%) and was not correlated with low FIX levels. However, FIX testing was limited during bleeding events. In literature, in 2 case series consisting of 36 and 25 surgical procedures respectively, 4,5 higher percentages of clinically relevant bleeding events as defined in our study have been reported (4-8.3%). In addition, most of these included patients underwent an orthopaedic surgical procedure. Contrastingly, in a cohort of 74 haemophilia B patients undergoing 81 surgical procedures, no red blood cell transfusions were reported and haemostatic efficacy was rated as excellent by surgical teams. 9 In this study, also different minor and major surgical procedures were included, which was similar compared to our cohort.
Exceptions are made for certain surgical procedures as a recent report by Kapadia et al showed that lower extremity total joint arthroplasty leads to significantly more red blood cell transfusions in haemophilia patients (15.1%) in comparison with a large matched cohort without a known bleeding history (9.8%); OR 1.60 (95% CI 1.11-2.31). We conclude that there may be growing evidence that it may be possible to maintain lower FIX target ranges in the perioperative setting.
| Perioperative FIX consumption and individualization of therapy
Although a significant proportion of the study population were underdosed without bleeding, a significant proportion was overdosed, especially >6 days after surgery with 59% of trough and steady-state FIX levels above target. Current costs of health care for society warrant avoidance of excessive dosing without a clinical effect. Overdosing may be prevented by more individualized dosing strategies that take patient, and surgical characteristics as well as individual pharmacokinetics of concentrates into account.
Children had a higher FIX consumption when compared to adults, which is explained by a large volume of distribution and higher clearance. 16 In prophylactic treatment, it has been proven that FIX consumption can be significantly reduced by individualization of dosing based on pharmacokinetic modelling. [17] [18] [19] [20] Several studies have also shown that preoperative dosing based on an individual pharmacokinetic profile is safe, effective and applicable. 5, 21 However, the actual challenge is to implement iterative pharmacokinetic-guided FIX con- Pharmacokinetic-guided dosing may help attain this goal, as lowering of FIX target ranges as set in such a study could be achieved reliably.
Moreover, PK guidance may also decrease overdosing in the last days of the perioperative period. Therefore, we suggest that construction of population pharmacokinetic models and dosing according to these models will lead to more exact dosing in order to achieve FIX target ranges. Moreover, PK-guided dosing may be able to support studies aiming to refine and possibly lower current target ranges in haemophilia B, thus leading towards overall optimization of perioperative management in haemophilia B.
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